Table 3.

Immunotherapy duration, clinical follow-up, immunotherapy termination

	Nivolumab+TACE (n=31)	Nivolumab only (All matched n=104)
	Number (%) or median (Range)		P value
Duration immunotherapy (months)	8.3 (0.5–40.1)	3.3 (0.4–35.9)	0.009*
Clinical follow-up after nivolumab initiation (months)	12.6 (1.3–40.6)	7.5 (0.5–47.8)	0.26
Ongoing nivolumab at last follow-up	13 (42)	23 (22)	0.04
Discontinued treatment	18 (58)	80 (77)	0.07
Disease progression	3 (9.7)	39 (38)	0.004*
Study drug toxicity	0 (0)	9 (8.7)	0.12
Complete Response	1 (3.2)	1 (1.0)	0.41
Clinical deterioration	4 (13)	2 (1.9)	0.03†
Death	5 (16)‡	3 (2.9)	0.02†
Other	5 (16)§	14 (13)*	0.77

*Statistically significant p-value <0.01

†Statistically significant p-value <0.05

‡2/5 deaths in setting of progression of disease

§4 patients successfully bridged to transplant.

TACE, transarterial chemoembolization.